The biotechnology sector in North Carolina continues to lead global medical innovation, as highlighted by the selection of the June 2026 Patent of the Month. This prestigious honor has been awarded to Belhaven BioPharma Inc. for their newly granted patent, titled “Medical counter measures including dry powder formulations and associated methods” (U.S. Patent No. 12616807). This landmark patent marks a monumental shift in how emergency medical countermeasures and life-saving drugs are stabilized, carried, and administered during critical healthcare crises.
Belhaven BioPharma, a clinical-stage pharmaceutical research firm headquartered in Raleigh, North Carolina, developed this proprietary technology to provide a fast, safe, and entirely needle-free alternative to traditional emergency therapeutics. By transitioning critical emergency medications from traditional liquid injections to an engineered dry powder nasal delivery system, this invention directly solves long-standing vulnerabilities in emergency medicine, such as the rapid degradation of liquid formulations under extreme temperatures and patient hesitancy stemming from needle phobia.
A Revolutionary Leap in Medical Countermeasures
What makes this patented invention so exceptionally innovative is its multi-faceted approach to overcoming the limits of current emergency delivery systems, such as traditional liquid auto-injectors. Key innovative features of the patent include:
- Unmatched Thermal Stability: Traditional liquid medications, including epinephrine, degrade rapidly when exposed to heat or light. Belhaven BioPharma’s dry powder formulation is highly temperature-resistant, ensuring a long shelf life and enabling the medication to be safely carried in hot climates or stored without refrigeration.
- Passive Nasal Deposition: The system utilizes an intuitive, single-use intranasal device engineered to achieve over 95 percent drug deposition within the nasal cavity. Crucially, it functions as a passive device, meaning it successfully delivers the full therapeutic dose regardless of the patient’s airflow or orientation, making it highly effective even if the recipient is completely unconscious.
- Elimination of Needle Phobia and Dosing Delays: By providing an easy-to-use nasal powder, the invention eliminates the fear, pain, and complexity associated with needles, allowing bystanders, caregivers, or patients to administer treatment immediately when every second counts.
Why It Captured North Carolina’s Patent of the Month for June 2026
The decision to award this invention the North Carolina Patent of the Month for June 2026 reflects its profound clinical utility and its immense contribution to the state’s economic and scientific landscape. Issued in May 2026, the patent arrives on the heels of major milestones for the Raleigh-based company, which recently advanced its flagship dry powder epinephrine program, Nasdepi, into critical clinical phases. As North Carolina solidifies its reputation as a premier global hub for life sciences and drug-device combination products, Belhaven BioPharma’s patent stands out as a prime example of local research translating into disruptive global healthcare solutions. By addressing critical gaps in emergency care, the invention brings substantial distinction to the state’s biotech ecosystem and promises to save countless lives worldwide.
U.S. R&D Tax Credit Eligibility for Practical Applications
From a commercial and financial perspective, the continuous practical applications and development of the technology described in this patent serve as excellent groundwork for claiming the federal Research and Development (R&D) Tax Credit in the United States under Internal Revenue Code Section 41. To qualify, a company’s activities must pass a four-part test, which includes demonstrating that the research is intended to discover information to eliminate technical uncertainty, relies on hard sciences, and involves a process of experimentation. Belhaven BioPharma’s ongoing efforts to optimize the dry powder particle size distribution, test formulation stability under varied atmospheric conditions, and conduct clinical biocomparability trials against traditional intramuscular injections are textbook examples of qualified research activities (QRAs). Consequently, the company can claim significant tax credits against qualified research expenses (QREs), including the salaries of the formulation scientists and chemical engineers involved, the cost of raw materials consumed during iterative batch testing, and third-party contract research organization (CRO) fees utilized to validate the safety and efficacy of this innovative nasal delivery platform.
